文献速递肿瘤 PET/CT放射性药物与辐射防护

18F-FDG PET显像可视化临床前模型中系统性STING激动剂诱导的淋巴细胞活化

18F-FDG PET Visualizes Systemic STING Agonist-Induced Lymphocyte Activation in Preclinical Models.
PubMed 文献 · J Nucl Med · 2022-06-23

研究在C57BL/6小鼠中给予系统性STING激动剂后24小时行18F-FDG PET,观察脾脏摄取变化,并用单细胞RNA测序和流式细胞术分析免疫细胞。结果显示STING激动剂显著提高脾脏18F-FDG摄取,脾脏SUVmax均值由对照组的1.90升至4.55(P<0.0001),并富集糖酵解转录特征;在荷瘤小鼠中STING激动剂显著延迟肿瘤生长并增加次级淋巴器官的18F-FDG摄取。作者认为18F-FDG PET可能为在全身水平测量系统性STING激动剂的药效学效应提供广泛适用的方法。

要点

  • 系统性STING激动剂使小鼠脾脏18F-FDG摄取显著升高,SUVmax均值对照组1.90 vs 给药组4.55(P<0.0001)。
  • STING激动剂处理后脾脏T、B淋巴细胞富集糖酵解转录特征,与免疫细胞活化标志物诱导相关。
  • 荷瘤小鼠中STING激动剂显著延迟肿瘤生长并增加次级淋巴器官18F-FDG摄取。

核心结论

  • 研究揭示了STING信号与免疫代谢之间此前未知的功能联系,并提示18F-FDG PET可能为在全身水平测量系统性STING激动剂的药效学效应及指导其临床开发提供广泛适用的方法。

研究设计与样本

  • 临床前研究:C57BL/6小鼠接受系统性STING激动剂后24小时行18F-FDG PET,给药后6小时取脾细胞行单细胞RNA测序和流式细胞术分析。
  • 对STING激动剂处理小鼠的总脾细胞及免疫磁珠富集的脾脏B、T淋巴细胞行γ计数测定18F-FDG摄取。
  • 在荷前列腺癌或胰腺癌肿瘤的小鼠中评估STING激动剂对18F-FDG摄取、T淋巴细胞活化标志物水平及肿瘤生长的影响。

主要发现

  • 小鼠系统性给予结构不同的STING激动剂后脾脏18F-FDG摄取显著增加,对照组脾脏SUVmax均值1.90(范围1.56-2.34)vs STING激动剂处理组4.55(范围3.35-6.20),P<0.0001。
  • 对系统性STING激动剂处理小鼠免疫细胞的单细胞转录和流式细胞术分析显示,T和B淋巴细胞均富集糖酵解转录特征,且与免疫细胞活化标志物的诱导相关。
  • 荷瘤小鼠中给予STING激动剂显著延迟肿瘤生长并增加次级淋巴器官的18F-FDG摄取。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Stimulator of interferon genes (STING) is a mediator of immune recognition of cytosolic DNA, which plays important roles in cancer, cytotoxic therapies, and infections with certain pathogens. Although pharmacologic STING activation stimulates potent antitumor immune responses in animal models, clinically applicable pharmacodynamic biomarkers that inform of the magnitude, duration, and location of immune activation elicited by systemic STING agonists are yet to be described. We investigated whether systemic STING activation induces metabolic alterations in immune cells that can be visualized by PET imaging. Methods: C57BL/6 mice were treated with systemic STING agonists and imaged with 18F-FDG PET after 24 h. Splenocytes were harvested 6 h after STING agonist administration and analyzed by single-cell RNA sequencing and flow cytometry. 18F-FDG uptake in total splenocytes and immunomagnetically enriched splenic B and T lymphocytes from STING agonist-treated mice was measured by γ-counting. In mice bearing prostate or pancreas cancer tumors, the effects of STING agonist treatment on 18F-FDG uptake, T-lymphocyte activation marker levels, and tumor growth were evaluated. Results: Systemic delivery of structurally distinct STING agonists in mice significantly increased 18F-FDG uptake in the spleen. The average spleen SUVmax in control mice was 1.90 (range, 1.56-2.34), compared with 4.55 (range, 3.35-6.20) in STING agonist-treated mice (P < 0.0001). Single-cell transcriptional and flow cytometry analyses of immune cells from systemic STING agonist-treated mice revealed enrichment of a glycolytic transcriptional signature in both T and B lymphocytes that correlated with the induction of immune cell activation markers. In tumor-bearing mice, STING agonist administration significantly delayed tumor growth and increased 18F-FDG uptake in secondary lymphoid organs. Conclusion: These findings reveal hitherto unknown functional links between STING signaling and immunometabolism and suggest that 18F-FDG PET may provide a widely applicable approach toward measuring the pharmacodynamic effects of systemic STING agonists at a whole-body level and guiding their clinical development.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Le TM, Lee HR, Abt ER, et al. 18F-FDG PET Visualizes Systemic STING Agonist-Induced Lymphocyte Activation in Preclinical Models. J Nucl Med. 2022. PMID: 35738905. doi:10.2967/jnumed.122.264121

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。